ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

Cinnamaldehyde Derivative (CB-PIC) Sensitizes Chemo-Resistant Cancer Cells to Drug-Induced Apoptosis via Suppression of MDR1 and its Upstream STAT3 and AKT Signalling

(2015) Jianzhong Xi et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

(2015) Rishil J. Kathawala et al.   DRUG RESISTANCE UPDATES

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

(2015) Guotai Xu et al.   NATURE

MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer

(2015) Xiaoqian Yang et al.   Scientific Reports

Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics

(2015) Maximilian Boesch et al.   Stem Cells Translational Medicine

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer

(2015) Jung-Min Lee et al.   Frontiers in Oncology

Genomic profile of ovarian carcinomas

(2014) Francesca Micci et al.   BMC CANCER

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance

(2014) J. E. Jaspers et al.   CANCER RESEARCH

PARP Inhibitors as P-glyoprotein Substrates

(2014) Denise Lawlor et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

(2014) Joyce F Liu et al.   LANCET ONCOLOGY

Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

(2014) Carin K. Ingemarsdotter et al.   Molecular Oncology

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

(2014) Selvi Durmus et al.   PHARMACEUTICAL RESEARCH

7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors

(2013) Raffaella Cincinelli et al.   BIOORGANIC & MEDICINAL CHEMISTRY

ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas

(2013) Sharon E. Johnatty et al.   GYNECOLOGIC ONCOLOGY

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

(2013) N. Johnson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

(2012) E Dean et al.   BRITISH JOURNAL OF CANCER

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

(2012) G Smith et al.   BRITISH JOURNAL OF CANCER

A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors

(2012) R. J. Kelly et al.   ONCOLOGIST

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells

(2011) Till Krech et al.   CANCER LETTERS

Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

(2011) N. Syed et al.   CANCER RESEARCH

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas

(2011) D. A. Zajchowski et al.   MOLECULAR CANCER THERAPEUTICS

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MDR1 C2005T polymorphism changes substrate specificity

(2010) Lijuan Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

(2010) R. J. Kelly et al.   CLINICAL CANCER RESEARCH

Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model

(2010) M. N. Fransson et al.   DRUG METABOLISM AND DISPOSITION

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function

(2009) Li-yang Tao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study

(2009) Hee Seung Kim et al.   GYNECOLOGIC ONCOLOGY

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

(2008) H. Chang et al.   ANNALS OF ONCOLOGY

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA